Priority 15 from the Psoriasis PSP
| UNCERTAINTY: Could gene therapy help to treat psoriasis? (JLA PSP Priority 15) | |
|---|---|
| Overall ranking | 15 |
| JLA question ID | 0072/15 |
| Explanatory note | Not available for this PSP |
| Evidence |
Han Evidence that apolipoprotein E (ApoE) polymorphisms are associated with the risk of psoriasis, especially ε2 and ε3 alleles. Further studies are needed. Jia 2013 This meta-analysis evidenced that the TNF-a –238 and –308 promoter polymorphisms may play different roles in conferring susceptibility to psoriasis. Further functional and well-designed studies should be conducted to confirm these results. Lee 2013 This meta-analysis evidenced that the IL-23R (rs11209026 and rs7530511) polymorphisms are associated with psoriasis risk in Europeans and that the IL-12B (rs6887695 and rs3212227) polymorphisms are associated with susceptibility to psoriasis in Europeans. Further studies needed. Lee 2015 This meta-analysis provided evidence for the vascular endothelial growth factor VEGF +405 C/G polymorphism conferring susceptibility to psoriasis in Asians, with the -460 C/T and -1154 A/G polymorphisms conferring susceptibility to psoriasis in Europeans. Further investigation of the associations between VEGF polymorphisms and psoriasis susceptibility needed. See data sheet for list of evidence considered. |
| Health Research Classification System category | Skin |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | What gene therapy is being developed to help Psoriasis sufferers? |
| Submitted by | 5 uncertainties were submitted around this question |
| PSP information | |
|---|---|
| PSP unique ID | 0072 |
| PSP name | Psoriasis |
| Total number of uncertainties identified by this PSP. | 55 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 17 September 2018 |